Lasker Awards Honor Advances in Modern Immunology
The prizes recognized the discoverers of B and T lymphocytes, pioneers in genetic engineering to fight breast cancer, and a nonprofit that helps get vaccines to the world ’s poorest children. (Source: NYT Health)
Source: NYT Health - September 10, 2019 Category: Consumer Health News Authors: Knvul Sheikh Tags: Lasker Awards Breast Cancer Vaccination and Immunization Immune System Children and Childhood your-feed-science Herceptin (Drug) Third World and Developing Countries Lymph Nodes and Lymphatic System Genetics and Heredity Thymus Gland Source Type: news
Laskers Go to Immunologists, Developers of Breast Cancer Therapy
The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the... (Source: The Scientist)
Source: The Scientist - September 10, 2019 Category: Science Tags: News & Opinion Source Type: news
UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news
Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs.
The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 7, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs.
The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news
Pledge to give all women same level of cancer care
Best practice to be shared across cancer networks Related items fromOnMedica Exercise and psychological treatments cut cancer fatigue Cancer patients using complementary meds die sooner Data don ’t support HRT for chronic disease prevention Benefit of Herceptin in more breast cancer cases New breast cancer drug ‘unaffordable’ for NHS (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 26, 2019 Category: UK Health Source Type: news
Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?
A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Kanjinti (Trastuzumab-anns for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 31, 2019 Category: Drugs & Pharmacology Source Type: news
MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer
The polycomb group gene MEL-18 may prevent trastuzumab resistance making it a potential novel biomarker for HER2+ breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Amgen and Allergan's MVASI ™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.). (Source: World Pharma News)
Source: World Pharma News - July 23, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Amgen, Allergan launch first anti-cancer biosims in U.S.
Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 19, 2019 Category: Pharmaceuticals Source Type: news
Ogivri (Trastuzumab-Dkst Injection, for Intravenous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 11, 2019 Category: Drugs & Pharmacology Source Type: news
Novel Conjugate Shows Promise in HER2-Expressing Cancers
Researchers tested the novel antibody-drug conjugate trastuzumab duocarmazine in patients with heavily pretreated HER2-expressing metastatic cancers, including breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
De-Escalation of Trastuzumab Remains Controversial in HER2+ Breast Cancer
After more than 7 years of follow-up, the phase III PHARE trial failed to show that 6 months of adjuvant trastuzumab therapy was noninferior to 12 months in patients with HER2+ early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
